Potential prognostic value of CSF-targeted proteomics across the Alzheimer’s disease continuum

• Published in: BMC geriatrics Vol. 24; no. 1; pp. 501 - 12
• Main Authors: Xu, Bingdong, Ling, Yitong, Liu, Leiyuan, Liu, Yujun, Lin, Yingze, Lyu, Jun, Zhang, Yusheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.06.2024; BioMed Central; BMC
• Subjects: Accuracy; Advertising executives; Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid beta-Peptides - metabolism; Biomarkers; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; Chromatography; Cognitive ability; Cognitive Dysfunction - cerebrospinal fluid; Cognitive Dysfunction - diagnosis; Cognitive function; Cohort Studies; Dementia; Development and progression; Disease Progression; Diseases; Female; Follow-Up Studies; Health aspects; Hippocampus; Humans; Male; Mass spectrometry; Mediation; Medical prognosis; Memory; Methods; Middle Aged; Neurodegenerative diseases; Neuropsychology; Older people; Peptides; Predictive Value of Tests; Prognosis; Proteins; Proteomics; Proteomics - methods; Scientific imaging; Software; Tau protein; tau Proteins - cerebrospinal fluid; China; Biomarkers; Prognosis; Alzheimer’s disease; Cognitive function; Proteomics

Core biomarkers for Alzheimer's disease (AD), such as Aβ42 and tau, have demonstrated high prognostic accuracy but do not fully capture the complex pathophysiology of AD. In this study, our objective was to identify novel cerebrospinal fluid (CSF) biomarkers using proteomics across the entire A...